DYNAVAX TECHNOLOGIES CORPORATION Financials Dynavax Technologies Corporation
Equities
DVAX
US2681582019
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.21 USD | +0.36% |
|
-5.00% | -19.81% |
| Apr. 01 | Dynavax Technologies Corporation Announces Chief Financial Officer Changes | CI |
| Feb. 23 | Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 479.7 | 490.3 | 1,688 | 1,358 | 1,807 | 1,467 | - | - |
| Enterprise Value (EV) 1 | 479.7 | 490.3 | 1,506 | 1,410 | 1,317 | 891.3 | 756.4 | 578.4 |
| P/E ratio | -2.65 x | -5.71 x | 24.7 x | 5.4 x | -280 x | 48.7 x | 31.1 x | 19.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13.6 x | 10.5 x | 3.84 x | 1.88 x | 7.78 x | 5.09 x | 4.23 x | 3.59 x |
| EV / Revenue | 13.6 x | 10.5 x | 3.43 x | 1.95 x | 5.67 x | 3.1 x | 2.18 x | 1.42 x |
| EV / EBITDA | - | - | 10.6 x | 4.86 x | -44.3 x | 36.4 x | 10.7 x | 5.68 x |
| EV / FCF | -3.31 x | -5.11 x | 4.62 x | 25.4 x | 13.7 x | 55.7 x | 11.6 x | 5.9 x |
| FCF Yield | -30.2% | -19.6% | 21.6% | 3.94% | 7.32% | 1.8% | 8.59% | 16.9% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 83,865 | 110,173 | 119,952 | 127,585 | 129,261 | 130,863 | - | - |
| Reference price 2 | 5.720 | 4.450 | 14.07 | 10.64 | 13.98 | 11.21 | 11.21 | 11.21 |
| Announcement Date | 3/11/20 | 2/25/21 | 2/28/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 35.22 | 46.55 | 439.4 | 722.7 | 232.3 | 288 | 346.7 | 408.3 |
| EBITDA 1 | - | - | 141.5 | 290.2 | -29.75 | 24.48 | 70.49 | 101.9 |
| EBIT 1 | -134.8 | -68.37 | 134.5 | 283.5 | -37.03 | -3.526 | 28.02 | 61.55 |
| Operating Margin | -382.87% | -146.87% | 30.6% | 39.23% | -15.94% | -1.22% | 8.08% | 15.07% |
| Earnings before Tax (EBT) 1 | -152.6 | -75.24 | 77.52 | 294.3 | -4.367 | 35.14 | 68.88 | 107.5 |
| Net income 1 | -155.9 | -75.24 | 76.71 | 293.2 | -6.389 | 27.4 | 51.89 | 82.56 |
| Net margin | -442.57% | -161.63% | 17.46% | 40.56% | -2.75% | 9.52% | 14.97% | 20.22% |
| EPS 2 | -2.160 | -0.7800 | 0.5700 | 1.970 | -0.0500 | 0.2300 | 0.3600 | 0.5633 |
| Free Cash Flow 1 | -145 | -96.01 | 326.1 | 55.58 | 96.46 | 16 | 65 | 98 |
| FCF margin | -411.79% | -206.25% | 74.2% | 7.69% | 41.53% | 5.56% | 18.75% | 24% |
| FCF Conversion (EBITDA) | - | - | 230.43% | 19.15% | - | 65.37% | 92.21% | 96.18% |
| FCF Conversion (Net income) | - | - | 425.03% | 18.96% | - | 58.4% | 125.26% | 118.7% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 2/25/21 | 2/28/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 108.3 | 195.1 | 114 | 256.5 | 167.7 | 184.5 | 46.92 | 60.25 | 69.51 | 55.6 | 54.98 | 78.37 | 87.84 | 65.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 16.07 | 80.72 | 30.76 | 128.2 | 61.4 | 63.14 | -30.25 | -3.405 | 5.116 | -8.491 | -12.33 | 5.674 | 11.71 | -8.574 |
| Operating Margin | 14.84% | 41.38% | 26.99% | 50% | 36.6% | 34.22% | -64.46% | -5.65% | 7.36% | -15.27% | -22.44% | 7.24% | 13.33% | -13.03% |
| Earnings before Tax (EBT) 1 | -28.43 | 100.6 | 32.86 | 129.4 | 64.09 | 67.97 | -23.72 | 4.207 | 14.15 | 0.996 | -4.259 | 14.57 | 19.56 | -0.999 |
| Net income 1 | -28.43 | 99.78 | 32.86 | 128.8 | 63.81 | 67.73 | -24.33 | 3.431 | 14.29 | 0.219 | -4.259 | 14.57 | 18.12 | -1.03 |
| Net margin | -26.26% | 51.15% | 28.83% | 50.2% | 38.04% | 36.71% | -51.85% | 5.69% | 20.56% | 0.39% | -7.75% | 18.59% | 20.62% | -1.57% |
| EPS 2 | -0.2400 | 0.5500 | 0.2200 | 0.8700 | 0.4300 | 0.4500 | -0.1900 | 0.0300 | 0.1000 | - | -0.0333 | 0.0800 | 0.1133 | -0.006670 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/28/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/23/23 | 5/2/23 | 8/3/23 | 11/2/23 | 2/22/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 52.4 | - | - | - | - |
| Net Cash position 1 | - | - | 181 | - | 490 | 576 | 711 | 889 |
| Leverage (Debt/EBITDA) | - | - | - | 0.1805 x | - | - | - | - |
| Free Cash Flow 1 | -145 | -96 | 326 | 55.6 | 96.5 | 16 | 65 | 98 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 22.4 | 4.07 | 9.48 | 7.14 | 4.1 | 4 | 4 | 4 |
| Capex / Sales | 63.6% | 8.75% | 2.16% | 0.99% | 1.77% | 1.39% | 1.15% | 0.98% |
| Announcement Date | 3/11/20 | 2/25/21 | 2/28/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.21
USD
Average target price
24.67
USD
Spread / Average Target
+120.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.81% | 1.47B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- DVAX Stock
- Financials Dynavax Technologies Corporation
